Full Description
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals. * Independent, unbiased, up-to-date - now with esketamine (Spravato)* Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine* New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar* Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug* Potential interactions and side effects summarized in comparison charts* With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek* Clearly written patient information sheets available for download as printable PDF filesThis book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.-------------------------------------------------------------------------------------------New in this edition:* Antidepressants chapter includes new section on esketamine (Spravato), recently approved for treatment-resistant depression; also updates to antidepressant use in pregnancy and SPARI drug interactions* Antipsychotics updates include new section on 5-HT2A inverse agonist antipsychotic (pimavanserin, Nuplazid) and comprehensive revision of augmentation strategies* Pharmacogenomics chapter fully revised with expanded dose adjustment recommendations* Chart of agents under investigation for treatment of substance use disorders fully revised, new agents include lofexidine (Lucemyra), Kadian, nortriptyline e-cigarettes* Unapproved treatments chapter with significant updates, including new sections on adrenergic agents in PTSD (doxazosin), antiflammatory agents in depression (pioglitazone, rosiglitazone, statins), and hormones in schizophrenia (raloxifene)* Expanded treatment options for extrapyramidal side effects include deutetrabenazine and valbenazine * New formulations and trade names include: Adzenys ER, Aristada, Austedo, Cotempla XR-ODT, Fanatrex FusePaq, Foquest, Ingrezza, Jornay PM, Mydayis, Nuplazid, Spravato, Sublocade, Zelapar
Contents
AntidepressantsSelective Serotonin Reuptake Inhibitors (SSRI) * NorepinephrineDopamine Reuptake Inhibitor (NDRI) * Serotonin NorepinephrineReuptake Inhibitor (SNRI) * Serotonin-2 Antagonists / ReuptakeInhibitors (SARI) * Serotonin-1A Agonist/Serotonin Reuptake Inhibitor(SPARI) * Serotonin Modulator and Stimulator (SMS) * Noradrenergic /Specific Serotonergic Antidepressants (NaSSA) * NonselectiveCyclic Antidepressants * Monoamine Oxidase Inhibitors * ReversibleInhibitor of MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B)Inhibitors (MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressantson Neurotransmitters / Receptors * PharmacologicalEffects of Antidepressants on Neurotransmitters / Receptors *Frequency of Adverse Reactions to Antidepressants at TherapeuticDoses * Antidepressant Doses and Pharmacokinetics * SwitchingAntidepressants * Antidepressant Augmentation StrategiesElectroconvulsive Therapy (ECT)Bright Light Therapy (BLT)Repetitive Transcranial Magnetic Stimulation (rTMS)AntipsychoticsSecond-Generation Antipsychotics / SGAs * Third-GenerationAntipsychotic / TGA * 5-HT21 Inverse Agonist Antipsychotic * First-Generation Antipsychotics / FGAs * Effects of Antipsychotics onNeurotransmitters / Receptors * Pharmacological Effects of Antipsychoticson Neurotransmitters / Receptor Subtypes * Relative TolerabilityProfiles of Anti-psychotics * Frequency of Adverse Reactionsto Antipsychotics at Therapeutic Doses * Antipsychotic Doses andPharmacokinetics (Oral and Short-Acting Injections) * Comparison ofLong-Acting IM Antipsychotics * Switching Antipsychotics *Antipsychotic Augmentation StrategiesAntipsychotic-Induced Extrapyramidal Side Effects and TheirManagementExtrapyramidal Adverse Effects of Antipsychotics * TreatmentOptions for Extrapyramidal Side Effects * Effects on ExtrapyramidalSymptoms * Comparison of Agents for Treating Acute ExtrapyramidalSide Effects * Doses and Pharmacokinetics of Agents for TreatingAcute Extrapyramidal Side EffectsAnxiolytic (Antianxiety) AgentsBenzodiazepines * Comparison of the Benzodiazepines * BuspironeHypnotics / SedativesL-Tryptophan * Comparison of Hypnotics / SedativesMood StabilizersLithium * Anticonvulsants * Comparison of Anticonvulsants *Frequency of Adverse Reactions to Mood Stabilizers at TherapeuticDosesDrugs for ADHDPsychostimulants * Atomoxetine * Comparison of Drugs for ADHD *2 Agonists * Augmentation Strategies in ADHDDrugs for Treatment of DementiaCholinesterase Inhibitors * Memantine * Comparison of Drugs forTreatment of DementiaSex-Drive DepressantsComparison of Sex-Drive DepressantsDrugs of AbuseAlcohol * Stimulants * Hallucinogens * Opioids * Inhalants / Aerosols* Gamma-hydroxybutyrate (GHB) / Sodium Oxybate * Flunitrazepam(Rohypnol) * Nicotine / TobaccoTreatment of Substance Use DisordersAcamprosate * Disulfiram * Naltrexone * Buprenorphine * Methadone *Pharmacotherapy for Nicotine / Tobacco Use Disorder * Comparisonof Treatments for Nicotine / Tobacco Use DisorderUnapproved Treatments of Psychiatric DisordersAdrenergic Agents * Anti-Inflammatory Agents * DopaminergicAgents * GABA Agents / Anticonvulsants *Hormones * NMDA Agents * 5-HT3 Antagonists * MiscellaneousNatural Health ProductsPharmacogenomic Information for Common Psychotropic DrugsGlossaryDrug Use in Pregnancy and Effects on Breast MilkPatient Information SheetsAppendix:Neuroscience-Based NomenclatureIndex of Drugs
